Albeit early in the 2023 proxy season process, Eli Lilly leads all other issuers with 7 no-action requests filed. Subjects include patent processes, DE&I data, majority voting, political spending and more $LLY #ProxySeason #ESG #CorpGov #DEI
Tidbit on the “more”: National Center for Public Policy has filed a shareholder proposal at Eli Lilly—again, a proposal the co. seeks to exclude—vis-à-vis reporting on the “risks of **supporting** abortion” (emphasis added). $LLY argues it’s excludable under ordinary business. #Abortion #CorpGov https://www.sec.gov/files/corpfin/no-action/14a-8/ncpprlilly122322-14a8-incoming.pdf